Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
The National Institute for Biotechnology in the Negev Ltd. has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is assigned to 1 examiner and 1 art unit.
PANCHOLI, MINJAL JITENDRAKUMA is the busiest examiner, with 1 pending matter. The single active record allows focused preparation around the biotechnology claims and the examiner’s objections.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PANCHOLI, MINJAL JITENDRAKUMA | 1 | — | — |
| LAFAVE, ELIZABETH ROSE | 1 | 65.6% | +43.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17430304 | KITS, COMPOSITIONS AND METHODS FOR EVALUATING IMMUNE SYSTEM STATUS | LAFAVE, ELIZABETH ROSE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17430304 | KITS, COMPOSITIONS AND METHODS FOR EVALUATING IMMUNE SYSTEM STATUS | LAFAVE, ELIZABETH ROSE | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 1684 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18848326 | BINDING MOLECULES SPECIFIC TO HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 | PANCHOLI, MINJAL JITENDRAKUMA | 1642 | §112 | Non-Final OA | — | Pending | Sep 18, 2024 |
| 17430304 | KITS, COMPOSITIONS AND METHODS FOR EVALUATING IMMUNE SYSTEM STATUS | LAFAVE, ELIZABETH ROSE | 1684 | §103§112 | Final Rejection | — | Pending | Aug 11, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe National Institute for Biotechnology in the Negev Ltd. has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Minjal Jitendrakuma Pancholi has the most, with 1 of The National Institute for Biotechnology in the Negev Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.